Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

Dr. Don Kotler discusses news from CROI about lipodystrophy, bone loss, and metabolic problems

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that...

New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will...

While HIV meds play a role in rates of cholesterol in HIV-positive people, it also appears diets rich in fat are likely culprits as well.  

Researchers have reported HIV-positive patients are less likely to benefit from lipid-lowering therapy than their HIV-negative counterparts.

Tibotec’s experimental NNRTI performs well in a clinical trial pitting it against standard-of-care Sustiva in treatment-naive patients. 

MD turns his gaze to the recent spate of data promoting the use of anti-herpes drugs to reduce HIV transmission and disease progression.